about
Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institutionPossible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.Epidemiology of systemic lupus erythematosus.Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort.Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosusRenal involvement in antiphospholipid syndromeThe Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and RepositoryIs Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et alRemission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohortManagement of non-renal non-neurologic persistent lupus activity in real world patients from ArgentinaApplying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspectiveJaccoud's arthropathy in SLE: findings from a Latin American multiethnic populationLong-term follow-up of antiphospholipid syndrome: real-life experience from a single center
P50
Q33411232-18C781FE-3D4E-4716-9148-676913225929Q33448450-154D8724-DC08-4496-BB5E-10DFBE88CDD5Q33455990-CB851FD2-6BD0-4B3A-A09A-84448FB08EDFQ33497970-F8E458AE-F545-48E8-A8CC-2759543700E8Q33555419-EDDE75FD-51A5-4FC0-993E-FAC172248939Q34184151-3EC724BD-6797-4DC6-85A6-B4F51DD0A6DDQ37875273-8CD0329C-FBD5-46B0-A98F-0E482E379499Q38362118-9E6601C7-8217-4C77-AB22-002E1464F695Q53839415-98359D77-76BF-43F2-96A0-5E8A21F72F10Q64912490-90DA2875-222A-4E1C-80F1-F6CDAA8EA087Q83842514-268770A9-E204-4867-AC15-B8DBFE8AD521Q86984388-08B8F161-6FC9-4622-9CA7-6DB99681DCA0Q88399624-463D56C9-B7B7-46E4-8057-4C2C1B31EDAEQ91016982-03288059-75E1-4842-8B3D-26384230CAC6Q91206528-8A4A5595-9B1E-4384-BACD-FF4B9A95EA61Q91834551-C7AF2EDA-9AE9-4082-B247-13E1BD9A8242Q92771606-F35E967A-6C75-4DCC-B3EE-C1836134391DQ93065562-21F6B87C-24BB-4DC8-BDE0-987E66A6C7EDQ96343082-B2D28C1E-E960-463A-86ED-A5EB174B97E5
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Guillermo J Pons-Estel
@ast
Guillermo J Pons-Estel
@en
Guillermo J Pons-Estel
@es
Guillermo J Pons-Estel
@nl
type
label
Guillermo J Pons-Estel
@ast
Guillermo J Pons-Estel
@en
Guillermo J Pons-Estel
@es
Guillermo J Pons-Estel
@nl
prefLabel
Guillermo J Pons-Estel
@ast
Guillermo J Pons-Estel
@en
Guillermo J Pons-Estel
@es
Guillermo J Pons-Estel
@nl
P21
P31
P496
0000-0002-0647-929X